Voyager Therapeutics, Inc. (NASDAQ:VYGR) Given Average Recommendation of “Buy” by Brokerages

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) have been given an average rating of “Buy” by the nine research firms that are covering the firm, Marketbeat Ratings reports. Eight analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $13.97.

Several brokerages have recently weighed in on VYGR. StockNews.com lowered shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Wells Fargo & Company set a $10.00 price objective on shares of Voyager Therapeutics and gave the stock an “overweight” rating in a research report on Wednesday, March 12th. Wedbush restated an “outperform” rating on shares of Voyager Therapeutics in a report on Wednesday, March 12th. Canaccord Genuity Group lowered their target price on Voyager Therapeutics from $14.00 to $12.00 and set a “buy” rating on the stock in a research note on Thursday, March 13th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Voyager Therapeutics in a report on Thursday, March 13th.

Institutional Trading of Voyager Therapeutics

Large investors have recently modified their holdings of the stock. Cubist Systematic Strategies LLC acquired a new stake in Voyager Therapeutics during the fourth quarter worth about $29,000. Tower Research Capital LLC TRC lifted its holdings in shares of Voyager Therapeutics by 133.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,383 shares of the company’s stock worth $31,000 after acquiring an additional 3,077 shares during the period. Picton Mahoney Asset Management boosted its position in shares of Voyager Therapeutics by 71.1% during the 4th quarter. Picton Mahoney Asset Management now owns 5,883 shares of the company’s stock worth $33,000 after acquiring an additional 2,444 shares in the last quarter. Oxford Asset Management LLP bought a new position in Voyager Therapeutics in the fourth quarter valued at approximately $60,000. Finally, Intech Investment Management LLC acquired a new position in Voyager Therapeutics during the third quarter valued at approximately $74,000. 48.03% of the stock is owned by institutional investors and hedge funds.

Voyager Therapeutics Stock Performance

Shares of NASDAQ:VYGR opened at $3.38 on Thursday. The company has a 50-day simple moving average of $4.47 and a 200 day simple moving average of $5.62. The company has a market capitalization of $186.60 million, a P/E ratio of 4.76 and a beta of 0.99. Voyager Therapeutics has a 52-week low of $3.36 and a 52-week high of $10.66.

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings data on Tuesday, March 11th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.24). Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. The business had revenue of $4.39 million during the quarter, compared to analyst estimates of $16.58 million. During the same period in the previous year, the business earned $1.25 earnings per share. As a group, equities analysts forecast that Voyager Therapeutics will post -0.91 earnings per share for the current year.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.